RE:RE:from IR/Sarah - thx to Kelsee from agorI'm pretty sure the "efficacy concerns" referenced from the earlier DSMB reports pertained to the possibility of negative efficacy, whereby if the DSMB noted a detrimintal effect on the Apabetalone arm, they could suggest the trail be stopped or adjusted (i.e.: the AB arm was experiencing 3 point mace events at a much faster clip than the control arm). They have not noted any such concerns - so no adjutments to protocol.
I don't think anything was wrong with any of the NR's - and there is no need for concern. We'll find out son enough if we meet the study endpoints.
In past DSMB news releases, some posters have erroneously thought that the efficacy comment meant that the drug was working as anticipated, which was definately not the case.
GLTA